Desipramine Hydrochloride and Filgrastim For Stem Cell Mobilization in Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Inclusion Criteria: * Patients eligible for autologous stem cell transplant for multiple myeloma; planned use of filgrastim (GCSF) for stem cell mobilization * Ability to give informed consent * Glomerular filtration rate (GFR) \> 30 ml/minute * Liver function tests \< 2.5 x upper limit of normal (ULN) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or less * Based on prior therapy patients will be classified into two categories: * Initial mobilizers with no exposure to alkylators * Remobilizers or with prior exposure to alkylators or with greater than 5 cycles of lenalidomide therapy prior to mobilization Exclusion Criteria: * Use of a monoamine oxidase inhibitor (MAO-I) during or within 2 weeks of desipramine therapy * Concomitant therapy with any drugs shown to have major interactions with desipramine * Concurrent use of drugs that are contraindicated with desipramine * Myocardial infarction in preceding 4 weeks; history of uncontrolled cardiac arrhythmias or family history of sudden cardiac death; baseline corrected QT (QTc) \> 460 msec * Active alcohol abuse * Bipolar disorder * Untreated active major depression * History of seizures in the past 3 years * Pregnancy and lactation; refusal to use adequate contraception * Uncontrolled thyroid disease * GCSF or pegfilgrastim use within 14 days prior to enrollment * Bortezomib, Revlimid or thalidomide use within 7 days of enrollment * Patients with sickle cell disease